Spectrum of Antibodies to Reproductive Hormones in Threatened Abortion

The spectrum of antibodies to reproductive hormones and the diagnostic significance of their measurements in threatened abortion during trimester I were studied. Enhanced production of antibodies to hormones was detected by ELISA in patients with threatened abortion ( N =44) in comparison with women...

Full description

Saved in:
Bibliographic Details
Published in:Bulletin of experimental biology and medicine 2014-10, Vol.157 (6), p.747-750
Main Authors: Menzhinskaya, I. V., Van’ko, L. V., Kiryushchenkov, P. A., Tambovtseva, M. A., Kashentseva, M. M., Sukhikh, G. T.
Format: Article
Language:English
Subjects:
Abortion
Abortion, Threatened - immunology
Adult
Area Under Curve
Biomedical and Life Sciences
Biomedicine
Cell Biology
Chorionic gonadotropin
Chorionic Gonadotropin - immunology
Enzyme-Linked Immunosorbent Assay
Female
Gonadotropin-Releasing Hormone - immunology
Hormones, Sex
Humans
Immunoglobulin G
Immunoglobulin G - immunology
Immunoglobulin M - immunology
Internal Medicine
Laboratory Medicine
Microbiology and Immunology
Pathology
Pituitary hormones
Pregnancy
Pregnant women
ROC Curve
Statistics, Nonparametric
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The spectrum of antibodies to reproductive hormones and the diagnostic significance of their measurements in threatened abortion during trimester I were studied. Enhanced production of antibodies to hormones was detected by ELISA in patients with threatened abortion ( N =44) in comparison with women with normal gestation ( N =30). These antibodies were detected more often than antiphospholipid antibodies ( p 0.8). Subclasses IgG 1 and IgG 2 predominated among IgG to chorionic gonadotropin. Presumably, antibodies to chorionic gonadotropin and gonadotropin-releasing hormone could serve as independent factors of threatened abortion risk during trimester I.
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-014-2658-y